Evidence map›Paper›PMID 34997889›Full record

ArticleJournal of neuro-oncology2022

Final results of the Choroid Plexus Tumor study CPT-SIOP-2000.

Johannes E Wolff, Stefaan W Van Gool, Tezer Kutluk, Blanca Diez, Rejin Kebudi, Beate Timmermann, Miklos Garami, Jaroslav Sterba, Gregory N Fuller, Brigitte Bison and 1 more

Erratum issued Registry-linked trialOpen access · hybridAbstract read
In one paragraph

Article in Journal of neuro-oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT00500890 (A Pilot Study Evaluating the Feasibility of an Intercontinental Phase III Chemotherapy Study for Patients With Choroid Plexus Tumors), which is not on this map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00500890 phase3terminatednot on this map

A Pilot Study Evaluating the Feasibility of an Intercontinental Phase III Chemotherapy Study for Patients With Choroid Plexus Tumors

TypeinterventionalSponsorM.D. Anderson Cancer CenterRan2005 to 2017Enrolled2ConditionsChoroid Plexus TumorsArmsCarboplatin, Cyclophosphamide, Etoposide, Vincristine, Radiation Therapy
3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Pediatric-Like Brain Tumors in Adults.Advances and technical standards in neurosurgery · 2024
    Review
  14. Article
  15. Article
  16. Review
  17. Distinct challenge: the case report of disseminated adult atypical choroid plexus papilloma.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2023
    Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 11 institutions in 6 countries.

Johannes E WolffUniversity of Regensburg, Regensburg, Germany.
Stefaan W Van GoolIOZK Immune Oncological Centre Cologne, Cologne, Germany.ORCID http://orcid.org/0000-0002-8102-5968
Tezer KutlukDepartment of Pediatric Oncology, Hacettepe University Medical School and Cancer Institute, Ankara, Turkey.ORCID http://orcid.org/0000-0002-1918-4407
Blanca DiezNeuro Oncology Program, Institute of Neurological Research, FLENI, Buenos Aires, Argentina.ORCID http://orcid.org/0000-0002-7115-7000
Rejin KebudiPediatric Hematology-Oncology, Oncology Institute, Istanbul University, Istanbul, Turkey.ORCID http://orcid.org/0000-0003-4344-8174
Beate TimmermannDepartment of Particle Therapy, University Hospital Essen, West German Proton Therapy Centre Essen (WPE), West German Cancer Center (WTZ), German Cancer Consortium (DKTK), Essen, Germany.ORCID http://orcid.org/0000-0003-2274-2008
Miklos Garami2nd Department of Pediatrics, Semmelweis University, Budapest, Hungary.ORCID http://orcid.org/0000-0003-4298-2746
Jaroslav SterbaDepartment of Pediatric Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic.ORCID http://orcid.org/0000-0002-8482-8352
Gregory N FullerDepartments of Neuropathology and Neuroradiology, MD Anderson Cancer Center, Houston, USA.ORCID http://orcid.org/0000-0001-9447-2647
Brigitte BisonDepartment of Neuroradiology, University Hospital of Augsburg, Augsburg, Germany.ORCID http://orcid.org/0000-0001-5849-8671
Uwe R KordesDepartment of Pediatric Hematology and Oncology, University Medical Center Hamburg, Hamburg, Germany. u.kordes@uke.de.ORCID http://orcid.org/0000-0001-6375-2320
AbbVie (United States) · USDeutschen Konsortium für Translationale Krebsforschung · DEFundación para la Lucha contra las Enfermedades Neurológicas de la Infancia · ARHacettepe University · TRIstanbul University · TRMasaryk University · CZSemmelweis University · HUThe University of Texas MD Anderson Cancer Center · USUniversität Hamburg · DEUniversity Hospital Augsburg · DEUniversity Hospital Cologne · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionStandards for chemotherapy against choroid plexus tumors (CPT) have not yet been established.

methodsCPT-SIOP-2000 (NCT00500890) was an international registry for all CPT nesting a chemotherapy randomization for high-risk CPT with Carboplatin/Etoposide/Vincristine (CarbEV) versus Cyclophosphamide/Etoposide/Vincristine (CycEV). Patients older than three years were recommended to receive irradiation: focal fields for non-metastatic CPC, incompletely resected atypical choroid plexus papilloma (APP) or metastatic choroid plexus papilloma (CPP); craniospinal fields for metastatic CPC/APP and non-responsive CPC. High risk was defined as choroid plexus carcinoma (CPC), incompletely resected APP, and all metastatic CPT. From 2000 until 2010, 158 CPT patients from 23 countries were enrolled.

resultsFor randomized CPC, the 5/10 year progression free survival (PFS) of patients on CarbEV (n = 20) were 62%/47%, respectively, compared to 27%/18%, on CycEV (n = 15), (intention-to-treat, HR 2.6, p = 0.032). Within the registry, histological grading was the most influential prognostic factor: for CPP (n = 55) the 5/10 year overall survival (OS) and the event free survival (EFS) probabilities were 100%/97% and 92%/92%, respectively; for APP (n = 49) 96%/96% and 76%/76%, respectively; and for CPC (n = 54) 65%/51% and 41%/39%, respectively. Without irradiation, 12 out of 33 patients with CPC younger than three years were alive for a median of 8.52 years. Extent of surgery and metastases were not independent prognosticators.

conclusionsChemotherapy for Choroid Plexus Carcinoma is feasible and effective. CarbEV is superior to CycEV. A subset of CPC can be cured without irradiation.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsChoroid Plexus NeoplasmsRandomized Controlled Trials as TopicCarcinomaEtoposideHumansRegistriesTreatment OutcomeVincristineEtoposideVincristineChemotherapyChoroid plexus tumorsIrradiationLi–Fraumeni syndrome

Identifiers

PMID34997889
PMCPMC8860833
OpenAlexW4205943972

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.